Oncotarget

Research Papers:

Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population

Fei Liu, Limei Luo, Yonggang Wei, Wentao Wang, Tianfu Wen, Jiayin Yang, Mingqing Xu and Bo Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:16488-16497. https://doi.org/10.18632/oncotarget.14870

Metrics: PDF 1395 views  |   HTML 1063 views  |   ?  


Abstract

Fei Liu1,*, Limei Luo2,*, Yonggang Wei1, Wentao Wang1, Tianfu Wen1, Jiayin Yang1, Mingqing Xu1, Bo Li1

1Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China

2Department of Clinical Immunological Laboratory, West China Hospital, Sichuan University, 610041, China

*These authors contributed equally to this work

Correspondence to:

Bo Li, email: cdlibo688@163.com

Yonggang Wei, email: wyonggang688@163.com

Keywords: hepatocellular carcinoma, VEGFA, polymorphism, susceptibility, clinical outcome

Received: September 06, 2016     Accepted: January 16, 2017     Published: January 27, 2017

ABSTRACT

Vascular endothelial growth factor A (VEGFA) is an important angiogenesis regulator, which plays an important role in angiogenesis and progression of tumor, including hepatocellular carcinoma (HCC). We aimed at determining whether single nucleotide polymorphisms of VEGFA gene influence the development and clinical outcomes of HCC. We analyzed four potential functional polymorphisms (936C/T, 634G/C, 1612G/A, 2578C/A) of VEGFA gene in 476 HCC patients and 526 controls using matrix-assisted laser desorption ionization time-of-flight mass spectrometry method. Serum VEGF levels were measured by enzyme-linked immunosorbent assay. The Kaplan-Meier methods with log-rank test and Cox regression models were used to compare survival of resected HCC patients according to the genotype. We found that only the VEGFA 2578C/A polymorphism was significantly associated with decreased risk of HCC (AA/AC vs. CC; adjusted OR = 0.69, 95% CI = 0.51−0.93). Furthermore, the 2578C/A polymorphism was associated with significantly decreased postoperative recurrence (AA/AC vs. CC, adjusted OR = 0.51; 95% CI, 0.29−0.88) and improved overall survival (AA/AC vs. CC, adjusted HR = 0.27, 95% CI = 0.13−0.52) of resected HCC patients. In addition, the VEGF serum levels in HCC patients were significantly higher than those in healthy controls, although no significant association between VEGFA genotype and serum levels of VEGF was observed. These results suggest that the VEGFA 2578 C/A polymorphism may play a potential role in the development and clinical outcome of HCC among Chinese Han population.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14870